Tag Archives: KPTI

Karyopharm Therapeutics (KPTI) Receives a Buy from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $30. The company’s shares closed on Friday at $15.01. According to TipRanks.com, White is a 5-star

H.C. Wainwright Maintains a Buy Rating on Karyopharm Therapeutics (KPTI)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $30. The company’s shares opened today at $18.46. White said: “We base our $30 price target

Robert W. Baird Believes Karyopharm Therapeutics (NASDAQ: KPTI) Still Has Room to Grow

In a report released yesterday, Michael Ulz from Robert W. Baird reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $25. The company’s shares closed yesterday at $18.38, close to its 52-week high of $20.39.

Canaccord Genuity Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)

Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $27. The company’s shares opened today at $18.38, close to its 52-week high of $20.39. According to TipRanks.com, Lee

Analysts’ Top Healthcare Picks: KPTI, BLUE

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (NASDAQ: KPTI) and Bluebird Bio (NASDAQ: BLUE) with bullish sentiments. Karyopharm Therapeutics (NASDAQ: KPTI) H.C. Wainwright analyst Edward White maintained

H.C. Wainwright Believes Karyopharm Therapeutics (NASDAQ: KPTI) Won’t Stop Here

H.C. Wainwright analyst Edward White assigned a Buy rating to Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $30. The company’s shares opened today at $18.59, close to its 52-week high of $18.93. According to TipRanks.com, White